Drug Trial Radar · NCT05933824
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Jul 13, 2023
Primary completion
Apr 12, 2024
Study completion Apr 12, 2024
Sponsor
- Lead sponsor
- Shanxi Kangbao Biological Product Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Institute of Pathogen Biology, Beijing, China
- First posted
- Jul 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomized, placebo-controlled, single-administration, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of LP-98 injection in healthy subjects in a first-in-human clinical study
Conditions
- HIV (Human Immunodeficiency Virus)
Interventions
LP-98 injectionDrug
Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes from baseline in respiration rate of Vital SignsTime frame: Within 36 days after the first administration.
- Changes from baseline in blood pressure of Vital Signs.Time frame: Within 36 days after the first administration.
- Changes from baseline in body temperature of Vital Signs.Time frame: Within 36 days after the first administration.
- Changes from baseline in ECG PR intervalThe cardiac rhythm is showed in 12 LeadsTime frame: within 36 days after administration
- Changes from baseline in ECG QRS intervalThe cardiac rhythm is showed in 12 LeadsTime frame: within 36 days after administration
- Changes from baseline in ECG QT intervalThe cardiac rhythm is showed in 12 LeadsTime frame: within 36 days after administration
- Changes from baseline in Blood lactate of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in Pregnancy test of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in red blood cell count of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in white blood cell count of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in neutrophil count of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in lymphocyte count of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in platelet count of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in hemoglobin of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in PT of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in INR of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in APTT of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in direct bilirubin of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in ALT of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in AST of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in total protein of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in albumin of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in creatinine of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in glucose of Laboratory ExaminationTime frame: within 36 days after administration
- Changes from baseline in potassium of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in sodium of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in chlorine of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in urine specific gravity of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in urine pH of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in urine glucose of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in urine protein of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in urine ketone body of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in urine white blood cell of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in urine occult blood of Laboratory Examination.Time frame: within 36 days after administration
- Changes from baseline in CK of Laboratory ExaminationTime frame: within 36 days after administration
- Changes from baseline in CK-MB of Laboratory ExaminationTime frame: within 36 days after administration
- Changes from baseline in LDH of Laboratory ExaminationTime frame: within 36 days after administration
- Changes from baseline in ALP of Laboratory ExaminationTime frame: within 36 days after administration
- Changes from baseline in Triglyceride of Laboratory ExaminationTime frame: within 36 days after administration
- Changes from baseline in CHOL of Laboratory ExaminationTime frame: within 36 days after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital)
Zhengzhou, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.